Post-Surgical Management of Gynecologic Cancers

Immediate Post-Operative Assessment and Decision Algorithm

The National Comprehensive Cancer Network recommends determining the final pathologic stage and histologic subtype to dictate adjuvant chemotherapy, radiation therapy, or observation 1, 2, 3
The final surgical stage is based on findings from peritoneal washings, lymph node status, omental pathology, and depth of invasion, as recommended by the National Comprehensive Cancer Network 1, 2, 3
Histologic subtype and grade, such as endometrioid, serous, clear cell, mucinous, or carcinosarcoma, fundamentally alter treatment recommendations, according to the National Comprehensive Cancer Network 1, 2
The presence of lymphovascular space invasion influences adjuvant therapy decisions, as stated by the National Comprehensive Cancer Network 4
Residual disease status, whether complete cytoreduction was achieved, is crucial in determining the treatment plan, as recommended by the National Comprehensive Cancer Network 1, 2

For early-stage epithelial ovarian cancer (Stage IA-IB, Grade 1-2), observation is acceptable for favorable histology, while adjuvant platinum-based chemotherapy is recommended for Stage IB-IC or Grade 3, according to the National Comprehensive Cancer Network 1, 2
For advanced-stage epithelial ovarian cancer (Stage IC-IV), platinum-based combination chemotherapy is mandatory, with a carboplatin/paclitaxel regimen, as recommended by the National Comprehensive Cancer Network 1, 2, 3
For endometrial cancer, Stage IA, Grade 1-2, observation without adjuvant therapy is recommended, while Stage IB, Grade 1-2, may require vaginal brachytherapy if lymphovascular space invasion is present, according to the National Comprehensive Cancer Network 5, 4
For carcinosarcoma, adjuvant chemotherapy is recommended for all stages, given the aggressive nature of the disease, as stated by the National Comprehensive Cancer Network 6

If mucinous histology is identified, appendectomy should be performed to exclude gastrointestinal primary with ovarian metastases, as recommended by the National Comprehensive Cancer Network 2, 3
If clear cell histology is present in early-stage disease, adjuvant chemotherapy should be strongly considered due to the higher risk of recurrence, according to the National Comprehensive Cancer Network 1
If lymph nodes are positive, this upstages the disease and mandates systemic chemotherapy, regardless of other factors, as stated by the National Comprehensive Cancer Network 1, 2, 3

The National Comprehensive Cancer Network recommends a surveillance protocol that includes physical examination, CA-125 monitoring, and vaginal cytology for the first 2 years, every 3 months 5, 4
For years 3-5, the protocol includes physical examination every 6 months, and imaging only if clinically indicated by symptoms or exam findings, as recommended by the National Comprehensive Cancer Network 5, 4
After 5 years, annual physical examination and chest X-ray are recommended, according to the National Comprehensive Cancer Network 5, 4

Delaying adjuvant chemotherapy beyond 6-8 weeks post-operatively may compromise outcomes, as stated by the National Comprehensive Cancer Network 1
Relying solely on CA-125 for surveillance is not recommended, as physical examination and symptom assessment are equally important, according to the National Comprehensive Cancer Network 5